Abstract
Purpose: To investigate the preventive effect of resveratrol against renal pathological changes in a rat model of chronic kidney disease (CKD). Methods: CKD was induced by daily intragastric administration of adenine (200 mg/kg) for 1 month. The effect of 10, 15, and 20 mg/kg doses of resveratrol on the levels of parathyroid hormone, phosphorous, and fibroblast growth factor-23 (FGF-23) in rat urine samples after 2 months of adenine administration were analyzed using an auto-analyzer. Results: Resveratrol treatment significantly inhibited the adenine-mediated increase in serum parathyroid hormone, phosphorous and FGF-23 levels ( p < 0.002). In rats treated with 10, 15 and 20 mg/kg doses of resveratrol after adenine, urine protein/creatinine ratio was reduced to 5, 675.6 ± 2453.7, 4, 789.8 ± 1,534.9, and 1, 965 ± 576.8 mg/g, respectively. In the untreated and normal control groups, the respective values were 7, 004 ± 1, 653.3 and 1, 627.5 ± 568.7 mg/g. Treatment with resveratrol after administration of adenine inhibited increases in creatinine, blood urea nitrogen, and uric acid levels in a dose-dependent manner ( p < 0.002). Resveratrol treatment also inhibited adeninemediated increases in monocytes and inflammatory cells. Furthermore, resveratrol prevented renal tubule swelling and expansion induced by adenine administration. Conclusion: Resveratrol treatment prevent the renal pathological changes induced by adenine administration in a rat model of CKD by inhibiting FGF-23, parathyroid hormone, and phosphate. Thus, resveratrol may be of therapeutic importance for the treatment of CKD. Keyword: Parathyroid hormone, Phosphate, Creatinine, Monocytes, Chronic kidney disease, Fibroblast growth factor-23
Highlights
Chronic kidney disease (CKD) is associated with inflammation and hemodynamic changes that result in scarring of the renal tubules and interstitial spaces, and the development of end-stage renal disease [1]
Studies have shown that a prolonged increase in the serum levels of proteinuria and fibroblast growth factor-23 (FGF-23) is the main cause of end-stage renal disease [2,3]
This study examined the utility of resveratrol for treating CKD by suppressing the expression of inorganic phosphate, parathyroid hormone, and FGF-23 in a rat model
Summary
Chronic kidney disease (CKD) is associated with inflammation and hemodynamic changes that result in scarring of the renal tubules and interstitial spaces, and the development of end-stage renal disease [1]. High levels of inorganic phosphate, parathyroid hormone, and FGF-23 in the serum promote the development of CKD [5]. Another factor that contributes to the development of kidney and heart disease is the presence of high levels of protein in urine [6]. Resveratrol treatment inhibits the production of inducible nitric oxide synthase by human epithelial cells [10]. It prevents cartilage degradation in animal models of arthritis [11]. This study examined the utility of resveratrol for treating CKD by suppressing the expression of inorganic phosphate, parathyroid hormone, and FGF-23 in a rat model
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.